IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis

Marko Petržalka, Eva Meluzínová, Jana Libertínová, Hana Mojžišová, Jitka Hanzalová, Petra Ročková, Martin Elišák, Silvia Kmetonyová, Jan Šanda, Ondřej Sobek and Petr Marusič

PLOS ONE, 2022, vol. 17, issue 6, 1-16

Abstract: Background: The possibility to better predict the severity of the disease in a patient newly diagnosed with multiple sclerosis would allow the treatment strategy to be personalized and lead to better clinical outcomes. Prognostic biomarkers are highly needed. Objective: To assess the prognostic value of intrathecal IgM synthesis, cerebrospinal fluid and serum IL-2, IL-6, IL-10, chitinase 3-like 2 and neurofilament heavy chains obtained early after the onset of the disease. Methods: 58 patients after the first manifestation of multiple sclerosis were included. After the initial diagnostic assessment including serum and cerebrospinal fluid biomarkers, all patients initiated therapy with either glatiramer acetate, teriflunomide, or interferon beta. To assess the evolution of the disease, we followed the patients clinically and with MRI for two years. Results: The IL-2:IL-6 ratio (both in cerebrospinal fluid)

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0270607 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 70607&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0270607

DOI: 10.1371/journal.pone.0270607

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().